Patent · US Active

IC31 nanoparticles

US9248180B2 · kind B2 · utility

0Cited by

3References

17Claims

0Family size

Assignee

Valneva Austria GmbH · AT

Inventors

Benjamin Wizel · Rockville, US
Karin Riedl · Bezirk Krems an der Donau (Stadt), AT
Karen Lingnau · Wien, AT
Ursula Schlosser · Mittersill, AT
Jürgen Wruss · Wien, AT
Robert Schlegl · Siegenfeld, AT
Michael Weber · Wien, AT
Christoph Reinisch · Siegenfeld, AT
Ljubomir Paucz · Wien, AT
Christoph Klade · Wien, AT
Jee Loon Look · Boyds, US
Christian Ruiz · Gaithersburg, US
Robert Seid · San Francisco, US

Key dates

Filing date	Apr 22, 2014
Grant date	Feb 2, 2016
Priority date	—
Expiry date	Apr 22, 2034

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 μm.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.